An open-label, randomized, four-period, crossover study to assess the effect of SMC021 (0.8 mg recombinant salmon calcitonin/200 mg 5-CNAC) on the pharmacokinetics of ibuprofen 600 mg and paracetamol 1G and the effects of ibuprofen and paracetamol on the pharmacokinetics of SMC021 in healthy volunteers.

Trial Profile

An open-label, randomized, four-period, crossover study to assess the effect of SMC021 (0.8 mg recombinant salmon calcitonin/200 mg 5-CNAC) on the pharmacokinetics of ibuprofen 600 mg and paracetamol 1G and the effects of ibuprofen and paracetamol on the pharmacokinetics of SMC021 in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Calcitonin; Ibuprofen; Paracetamol
  • Indications Arthritis; Dysmenorrhoea; Osteoarthritis; Pain; Postmenopausal osteoporosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 22 Apr 2012 Results presented at the 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 22 Apr 2012 Status changed from recruiting to completed.
    • 13 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top